Lenvatinib Clinical Trials
75 recruitingDrug
Phase 250Phase 115Not Applicable7Phase 36Early Phase 13
Showing 1–20 of 75 trials
Recruiting
Phase 1Phase 2
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
Endometrial CancerEndometrial CarcinomaCancer of Endometrium+1 more
National Cancer Institute (NCI)60 enrolled1 locationNCT06253494
Recruiting
Phase 2
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Metastatic Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8+1 more
NRG Oncology240 enrolled318 locationsNCT05327686
Recruiting
Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled777 locationsNCT03486873
Recruiting
Phase 1Phase 2
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center49 enrolled7 locationsNCT06110793
Recruiting
Phase 3
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Carcinoma, Renal CellVon Hippel-Lindau Disease
Merck Sharp & Dohme LLC450 enrolled4 locationsNCT07405164
Recruiting
Phase 1
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
Hepatocellular Cancer
AbbVie232 enrolled22 locationsNCT06858813
Recruiting
Early Phase 1
Merck IIT: RRP Pembro and Lenvatinib
Pulmonary DiseaseRecurrent Respiratory PapillomatosisHuman Papilloma Virus
Yale University20 enrolled1 locationNCT04645602
Recruiting
Phase 1Phase 2
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC230 enrolled57 locationsNCT05319730
Recruiting
Phase 2
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
Thyroid CancerCancer of the Thyroid
Washington University School of Medicine34 enrolled1 locationNCT07092514
Recruiting
Phase 1Phase 2
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Cervical CancerUrothelial CarcinomaAdvanced Solid Tumor+3 more
GI Innovation, Inc.317 enrolled8 locationsNCT04977453
Recruiting
Phase 2
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
Neuroendocrine TumorsWell-Differentiated Neuroendocrine CarcinomaHigh Grade Neuroendocrine Carcinoma, Any Site
University of California, San Francisco29 enrolled1 locationNCT05746208
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Solid Tumor
Eisai Inc.182 enrolled58 locationsNCT04300556
Recruiting
Phase 2
Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma: a Phase 2 Study(HAIC-quad Trial)
Intrahepatic Cholangiocarcinoma (Icc)HAICDurvalumab
West China Hospital25 enrolled1 locationNCT06859684
Recruiting
Phase 1
Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
Unresectable Endometrial CarcinomaRecurrent Endometrial Carcinoma
Aaron Wolfson18 enrolled1 locationNCT05603910
Recruiting
Phase 2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
Biliary Tract CancerHepatocellular Carcinoma
AstraZeneca294 enrolled60 locationsNCT05775159
Recruiting
Phase 1Phase 2
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Merck Sharp & Dohme LLC1,200 enrolled21 locationsNCT02861573
Recruiting
Phase 2
Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
Carcinoma, Squamous CellAnorectal Cancer
University of Chicago35 enrolled1 locationNCT06669572
Recruiting
Not Applicable
Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
Unresectable Hepatocellular Carcinoma (HCC)
Bangladesh Medical University40 enrolled1 locationNCT07408804
Recruiting
Phase 1
A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
Hepatocellular Carcinoma
Zhejiang University72 enrolled2 locationsNCT05155189
Recruiting
Early Phase 1
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma
Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+30 more
M.D. Anderson Cancer Center15 enrolled1 locationNCT05041153